Cecilia Bozzetti

Summary

Affiliation: University of Parma
Country: Italy

Publications

  1. doi request reprint Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples
    Cecilia Bozzetti
    Medical Oncology Unit, University Hospital, Parma, Italy
    Diagn Cytopathol 41:595-8. 2013
  2. doi request reprint Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer
    Cecilia Bozzetti
    Medical Oncology Unit, University Hospital of Parma, Parma, Italy
    Lung Cancer 80:35-8. 2013
  3. pmc Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma
    C Bozzetti
    Medical Oncology Unit, Azienda Ospedaliero Universitaria, Via Gramsci 14, Parma 43126, Italy
    Br J Cancer 104:1372-6. 2011
  4. ncbi request reprint Biological parameters on computed tomography guided fine needle aspiration biopsy from peripheral primary non-small cell lung cancer
    Cecilia Bozzetti
    Divisione di Oncologia Medica, Azienda Ospedaliera di Parma, Via Gramsci 14, 43100 Parma, Italy
    Lung Cancer 35:243-7. 2002
  5. ncbi request reprint Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity
    Cecilia Bozzetti
    Deparment of Medical Oncology, University Hospital, Parma, Italy
    Am J Clin Oncol 29:171-7. 2006
  6. ncbi request reprint Loss of heterozygosity (LOH) in ovarian cancer
    C Bozzetti
    Department of Medical Oncology, University Hospital, Parma, Italy
    Int J Gynaecol Obstet 85:294-5. 2004
  7. ncbi request reprint HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma
    Cecilia Bozzetti
    Department of Medical Oncology, University Hospital, Parma, Italy
    Cancer 99:310-5. 2003
  8. doi request reprint Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers
    Marcello Tiseo
    Division of Medical Oncology, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Lung Cancer 67:355-60. 2010
  9. doi request reprint Is cytology reliable for epidermal growth factor receptor gene evaluation in non-small cell lung cancer?
    Cecilia Bozzetti
    Oncologia Medica, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    J Thorac Oncol 5:551-3. 2010
  10. doi request reprint Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer
    Marcello Tiseo
    Division of Medical Oncology, University Hospital of Parma, Italy
    J Thorac Oncol 3:1104-11. 2008

Collaborators

Detail Information

Publications18

  1. doi request reprint Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples
    Cecilia Bozzetti
    Medical Oncology Unit, University Hospital, Parma, Italy
    Diagn Cytopathol 41:595-8. 2013
    ....
  2. doi request reprint Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer
    Cecilia Bozzetti
    Medical Oncology Unit, University Hospital of Parma, Parma, Italy
    Lung Cancer 80:35-8. 2013
    ....
  3. pmc Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma
    C Bozzetti
    Medical Oncology Unit, Azienda Ospedaliero Universitaria, Via Gramsci 14, Parma 43126, Italy
    Br J Cancer 104:1372-6. 2011
    ..The aim of this study was to compare HER2 status in primary and paired metastatic sites of gastric adenocarcinoma...
  4. ncbi request reprint Biological parameters on computed tomography guided fine needle aspiration biopsy from peripheral primary non-small cell lung cancer
    Cecilia Bozzetti
    Divisione di Oncologia Medica, Azienda Ospedaliera di Parma, Via Gramsci 14, 43100 Parma, Italy
    Lung Cancer 35:243-7. 2002
    ..Moreover, in locally advanced or metastatic NSCLC immunocytochemistry could help to predict the response to chemotherapy and/or radiotherapy, avoiding ineffective treatments and supporting the development of more rational therapies...
  5. ncbi request reprint Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity
    Cecilia Bozzetti
    Deparment of Medical Oncology, University Hospital, Parma, Italy
    Am J Clin Oncol 29:171-7. 2006
    ..We evaluated the contribution of HER-2/neu gene amplification and other biologic markers in predicting response to different doses of neoadjuvant anthracycline-based chemotherapy...
  6. ncbi request reprint Loss of heterozygosity (LOH) in ovarian cancer
    C Bozzetti
    Department of Medical Oncology, University Hospital, Parma, Italy
    Int J Gynaecol Obstet 85:294-5. 2004
  7. ncbi request reprint HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma
    Cecilia Bozzetti
    Department of Medical Oncology, University Hospital, Parma, Italy
    Cancer 99:310-5. 2003
    ..The current study evaluated HER-2/neu amplification by FISH on cytologic samples obtained from distant metastatic lesions of breast carcinoma to update HER-2/neu characterization through a safe and easier procedure than biopsy...
  8. doi request reprint Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers
    Marcello Tiseo
    Division of Medical Oncology, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Lung Cancer 67:355-60. 2010
    ..Moreover, EGFR gene copy number and, potentially, also EGFR intron 1 polymorphism could aid in better prediction of EGFR TKI responsiveness in advanced NSCLC...
  9. doi request reprint Is cytology reliable for epidermal growth factor receptor gene evaluation in non-small cell lung cancer?
    Cecilia Bozzetti
    Oncologia Medica, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    J Thorac Oncol 5:551-3. 2010
    ..Epidermal growth factor receptor (EGFR) gene copy number has been proposed as predictor of response to epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer (NSCLC)...
  10. doi request reprint Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer
    Marcello Tiseo
    Division of Medical Oncology, University Hospital of Parma, Italy
    J Thorac Oncol 3:1104-11. 2008
    ..This study was designed to assess the role of (CA)n polymorphism in predicting the outcome of gefitinib treatment in advanced non-small cell lung cancer (NSCLC)...
  11. ncbi request reprint Determination of biological parameters on fine-needle aspirates from non-small cell lung cancer
    Cecilia Bozzetti
    Divisione di Oncologia Medica, Azienda Ospedaliera Universitaria di Parma, Parma, Italy
    Methods Mol Med 75:405-20. 2003
  12. ncbi request reprint Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas
    Rita Nizzoli
    Divisione di Oncologia Medica, Ospedale di Parma, Parma, Italy
    Diagn Cytopathol 28:142-6. 2003
    ..In this study, the false positivity of immunocytochemical technique represents the major criticism. In our experience, FISH remains the most objective and powerful technique for HER-2/neu assessment on breast cancer FNAs...
  13. doi request reprint Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites
    Cecilia Bozzetti
    Division of Medical Oncology, University Hospital of Parma, Parma, Italy
    J Thorac Oncol 3:18-22. 2008
    ..The possibility to perform FISH analysis on cytologic material obtained by fine-needle aspiration from superficial and visceral metastases would allow us to know the real EGFR status avoiding invasive diagnostic procedures...
  14. ncbi request reprint HER-2/neu evaluation by fluorescence in situ hybridization on destained cytologic smears from primary and metastatic breast cancer
    Rita Nizzoli
    Department of Medical Oncology, University Hospital, Parma, Italy
    Acta Cytol 49:27-30. 2005
    ..To evaluate HER-2/neu amplification by fluorescence in situ hybridization (FISH) (HER-2/neu by FISH) on archival cytologic smears stained with May-Gr├╝nwald-Giemsa (MGG) stain...
  15. doi request reprint Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study
    Antonino Musolino
    Medical Oncology Unit and Cancer Registry of Parma Province, University Hospital of Parma, Parma, Italy
    Cancer 117:1837-46. 2011
    ..Trastuzumab, which does not cross the blood-brain barrier, has been associated with this increased risk...
  16. ncbi request reprint Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role?
    Antonino Musolino
    Lung Cancer 50:419-20. 2005
  17. ncbi request reprint p73 and p53 pathway in human breast cancers
    Cecilia Bozzetti
    J Clin Oncol 25:1451-3; author reply 1453-4. 2007
  18. ncbi request reprint Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer
    Maura Loprevite
    Medical Oncology A, National Institute for Cancer Research, S Martino Hospital, Genoa, Italy
    Clin Cancer Res 13:6518-26. 2007
    ..Expression of the same proteins was also assessed on corresponding tissue samples for comparison. Moreover, EGFR gene mutations and copy number were analyzed...